Web6 apr. 2024 · Hutchmed stock rises 15% as fruquintinib meets one main goal in gastric cancer trial SA News Mon, Nov. 14, 2024 Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder WebFind the latest HUTCHMED (China) Limited (HCM.L) stock quote, history, news and other vital information to help you with your stock trading and investing.
Hutchmed Share Chat. Chat About HCM Shares - Stock Quote, …
Web4 mrt. 2024 · HCM Stock Overview HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. About the company Rewards Trading at 64.3% below our estimate of its fair value Revenue is forecast to grow 20.78% per year Risk … WebFor further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AІM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or ... acroclita
Hutchmed Ltd Stock Forecast, Predictions & Price Target
Web11 apr. 2024 · HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the … Web2 dagen geleden · HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented … acrocodia学名